A 17-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial Of Pregabalin For The Treatment Of Chronic Central Neuropathic Pain After Spinal Cord Injury.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Jan 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Nov 2016 Results of a retrospective analysis from NCT00394901, NCT00553475, NCT00407745, NCT00424372, NCT00553280, NCT01202227 studies, published in the Clinical Drug Investigation
20 May 2016 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information; JapicCTI101335)
03 May 2014 Results from a pooled analysis presented at the 33rd Annual Scientific Meeting of the American Pain Society.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com